文献速递肾小球疾病慢性肾脏病

方案肾活检在增殖性(III/IV型)狼疮性肾炎管理中的作用:方向错误!

Protocol kidney biopsy in the management of proliferative (class III/IV) lupus nephritis: barking up the wrong tree!
PubMed 文献 · Nephrol Dial Transplant · 2026-09-04

本文综述重复方案肾活检在增殖性(III/IV型)狼疮性肾炎管理中的证据,认为该实践基于错误假设且获益有限,建议以免疫学活动标志物(抗ds-DNA)和临床活动标志物(C3/C4)预测复发风险及指导免疫抑制调整。

要点

  • 方案肾活检在增殖性狼疮性肾炎管理中证据不足,获益有限。
  • 肾脏表现反映上游免疫学活动,而非直接决定管理决策。
  • 应关注抗ds-DNA和C3/C4等血清学活动标志物指导治疗。

核心结论

  • 重复方案肾活检在增殖性III/IV型狼疮性肾炎管理中基于错误证据且获益有限。
  • 应通过血清学活动标志物而非方案肾活检来评估疾病活动性。

研究设计与样本

  • 本文为针对重复方案肾活检在狼疮性肾炎中应用的深入综述。

主要发现

  • 尽管治疗手段进步,狼疮性肾炎患者进展至终末期肾病或死亡的数量未显著改变,复发是主要原因之一。
  • 每次复发均造成进一步肾损伤,促进进展性慢性肾脏病发展。
  • 方案肾活检实践基于答案在肾脏的假设,但肾脏仅反映上游免疫学 milieu 的降级效应。

临床怎么用

  • 治疗增殖性III/IV型狼疮性肾炎患者时,应关注抗ds-DNA水平和C3/C4补体水平以预测复发风险。
  • 根据血清学活动标志物决定何时减少或停用免疫抑制治疗,而非依赖方案肾活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lupus nephritis represents one of the most severe manifestations of systemic lupus erythematosus. Despite major advances in the therapeutical armamentarium over the last two decades, the number of patients reaching end stage kidney disease or dying has not changed significantly. One of the main reasons is that many patients relapse, and with each relapse, further damage is done to the kidney, contributing to the development of progressive chronic kidney disease. This has led to the increased practice of doing protocol biopsy to guide decision regarding risk for relapses and/or discontinuation of immunosuppression. However, this practice has been based on the assumption that the answer is in the kidney, while in reality the kidney reflects the downgrade effect of what is going on upstream, i.e. the immunological milieu. We provide an in-dept review on the use of repeat protocol kidney biopsies in LN with the hope to demonstrate that this practice is based on faulty evidence and of limited benefit in the management of patients with proliferative class III/IV lupus nephritis. Rather, physicians treating these patients should focus on markers of immunological activity (anti-ds-DNA levels) and clinical activity (C3/C4 complement levels), to better predict risk for relapses and in deciding when to reduce/discontinue immunosuppression. As such, this review represents a paradigm shift in the approach of evaluating activity in patients with LN, that is not done by performing protocol kidney biopsies, but rather by looking at the serological activity instead, and as such proposing a new vision on the subject that we believe will improve patient care and kidney outcomes.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zand L, Berti GM, Cara A, et al. Protocol kidney biopsy in the management of proliferative (class III/IV) lupus nephritis: barking up the wrong tree! Nephrol Dial Transplant. 2026. PMID: 42695989. doi:10.1093/ndt/gfag207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。